HANCOX, J., AYLING, K., BEDFORD, L., VEDHARA, K., ROBERTSON, J.F.R., YOUNG, B., DAS NAIR, R., SULLIVAN, F., SCHEMBRI, S., MAIR, F.M., LITTLEFORD, R. and KENDRICK, D., 2022. Psychological impact of lung cancer screening using a novel antibody blood test followed by imaging: the ECLS randomised controlled trial J Public Health (Oxf). fdac032 JAHAN M, BARTHOLOMEUZ T, MILBURN N, ROGERS V, SIBBERING M and ROBERTSON J, 2022. Transforming the 2-week wait (2WW) pathway: management of breast pain in primary care BMJ Open Qual. 11(1), e001634 ROBERTSON JF, EVANS A, HENSCHEN S, KIRWAN CC, JAHAN A, KENNY LM, DIXON JM, SCHMID P, KOTHARI A, MOHAMED O, FASCHING PA, CHEUNG KL, WUERSTLEIN R, CARROLL D, KLINOWSKA T, LINDEMANN JPO, MACDONALD A, MATHER R, MAUDSLEY R, MOSCHETTA M, NIKOLAOU M, ROUDIER MP, SARVOTHAM T, SCHIAVON G, ZHOU D and ZHOU L, 2020. A randomized, window of opportunity study comparing the effects of the novel oral SERD AZD9496 with fulvestrant in patients with ER+ HER2- primary breast cancer. Clin Cancer Res. QURESHI, N., DUTTON, B., WENG, S., SHEEHAN, C., CHORLEY, W., ROBERTSON, J.F.R., KENDRICK, D. and KAI, J., 2020. Improving primary care identification of familial breast cancer risk using proactive invitation and decision support Familial Cancer. First Published Online: 11 June 2020, SULLIVAN, F.M., MAIR, F.S., ANDERSON, W., ARMORY, P., BRIGGS, A., CHEW, C., DORWARD, A., HAUGHNEY, J., HOGARTH, F., KENDRICK, D., LITTLEFORD, R., MCCONNACHIE, A., MCCOWAN, C., MCMEEKIN, N., PATEL, M., RAUCHHAUS, P., RITCHIE, L., ROBERTSON, C., ROBERTSON, J., ROBLES-ZURITA, J., SARVESVARAN, J., SEWELL, H., SPROULE, M., TAYLOR, T., TELLO, A., TREWEEK, S., VEDHARA, K. and SCHEMBRI, S., 2020. Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging European Respiratory Journal. Online ahead of print: 30 July 2020, 2000670 MILIGY IM, TOSS MS, SHIINO S, ONI G, SYED BM, KHOUT H, TAN Q, GREEN AR, MACMILLAN RM, ROBERTSON JFR and RAKHA EM, 2020. The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ Br J Cancer: 123(10):1513-1520.. 123(10), 1513-1520 ROBERTSON JF, COLEMAN RE, CHEUNG KL, EVANS A, HOLCOMBE C, SKENE A, REA D, AHMED S, JAHAN A, HORGAN K, RAUCHHAUS P, LITTLEFORD R, CHEUNG SA, CULLBERG M, DE BRUIN EC, KOULAI L, LINDEMANN JPO, PASS M, RUGMAN P, SCHIAVON G, DEB R, FINLAY P, FOXLEY A and GEE JM, 2019. Proliferation and AKT activity biomarker analyses after Capivasertib (AZD5363) treatment of patients with ER+ invasive breast cancer (STAKT). Clinical cancer research : an official journal of the American Association for Cancer Research. (In Press.)
MASSION PP, HEALEY GF, PEEK LJ, FREDERICKS L, SEWELL HF, MURRAY A and ROBERTSON JF, 2016. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. NEGM OH, HAMED MR, SCHOEN RE, WHELAN RL, STEELE RJ, SCHOLEFIELD J, DILNOT EM, SHANTHA KUMARA HM, ROBERTSON JF and SEWELL HF, 2016. Human Blood Autoantibodies in the Detection of Colorectal Cancer. PloS one. 11(7), e0156971 MATHEW J, KARIA R, MORGAN DA, LEE AH, ELLIS IO, ROBERTSON JF and BELLO AM, 2016. Factors influencing local control in patients undergoing breast conservation surgery for ductal carcinoma in situ. Breast (Edinburgh, Scotland). 31, 181-185 (In Press.)
ELLIS MJ and ROBERTSON JF, 2016. Reply to T. Reinert et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(16), 1960-1 AGRAWAL A, ROBERTSON JFR, CHEUNG KL, GUTTERIDGE E, ELLIS IO, NICHOLSON RI and GEE JMW, 2015. Biological effects of fulvestrant on estrogen receptor positive human breast cancer: Short, medium and long-term effects based on sequential biopsies. International journal of cancer. Journal international du cancer. TOI M, WINER EP, BENSON JR, INAMOTO T, FORBES JF, VON MINCKWITZ G, ROBERTSON JF, GROBMYER SR, JATOI I, SASANO H, KUNKLER I, HO AY, YAMAUCHI C, CHOW LW, HUANG CS, HAN W, NOGUCHI S, PEGRAM MD, YAMAUCHI H, LEE ES, LARIONOV AA, BEVILACQUA JL, YOSHIMURA M, SUGIE T, YAMAUCHI A, KROP IE, NOH DY, KLIMBERG VS and , 2015. Personalization of loco-regional care for primary breast cancer patients (part 2). Future oncology (London, England). 11(9), 1301-5 ELLIS MJ, LLOMBART-CUSSAC A, FELTL D, DEWAR JA, JASIÓWKA M, HEWSON N, RUKAZENKOV Y and ROBERTSON JF, 2015. Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(32), 3781-7 MATHEW J, PRINSLOO P, AGRAWAL A, GUTTERIDGE E, MARENAH C, ROBERTSON JFR and CHEUNG KL, 2014. Pilot randomised study of early intervention based on tumour markers in the follow-up of patients with primary breast cancer. Breast (Edinburgh, Scotland). (In Press.)
MATHEW, J., PRINSLOO, P., AGRAWAL, A., GUTTERIDGE, E., MARENAH, C., ROBERTSON, J. F. R. and CHEUNG, K. L., 2014. Pilot randomised study of early intervention based on tumour markers in the follow-up of patients with primary breast cancer BREAST. 23(5), 567-572 ROBERTSON, JOHN F. R., LINDEMANN, JUSTIN, GARNETT, SALLY, ANDERSON, ELIZABETH, NICHOLSON, ROBERT I., KUTER, IRENE and GEE, JULIA M. W., 2014. A Good Drug Made Better: The Fulvestrant Dose-Response Story CLINICAL BREAST CANCER. 14(6), 381-389 JETT, JAMES R., PEEK, LAURA J., FREDERICKS, LYNN, JEWELL, WILLIAM, PINGLETON, WILLIAM W. and ROBERTSON, JOHN F. R., 2014. Audit of the autoantibody test, EarlyCDT (R)-Lung, in 1600 patients: An evaluation of its performance in routine clinical practice LUNG CANCER. 83(1), 51-55 MIDDLETON, CATRIN H., IRVING, WILLIAM, ROBERTSON, JOHN F. R., MURRAY, ANDREA, PARSY-KOWALSKA, CELINE B., MACDONALD, ISABEL K., MCELVEEN, JANE, ALLEN, JARED, HEALEY, GRAHAM F., THOMSON, BRIAN J., RYDER, STEPHEN J., HOLDENRIEDER, STEFAN and CHAPMAN, CAROLINE J., 2014. Serum Autoantibody Measurement for the Detection of Hepatocellular Carcinoma PLOS ONE. 9(8), ROBERTSON, J.F.R., FERRERO, J.M., BOURGEOIS, H., KENNECKE, H., DE BOER, R.H., JACOT, W., MCGREIVY, J., SUZUKI, S., ZHU, M., MCCAFFERY, I., LOH, E., GANSERT, J.L. and KAUFMAN, P.A., 2013. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial Lancet Oncology. 14(3), 228-235 CHAPMAN, C.J., THORPE, A.J., MURRAY, A., PARSY-KOWALSKA, C.B., ALLEN, J., STAFFORD, K.M., CHAUHAN, A.S., KITE, T.A., MADDISON, P. and ROBERTSON, J.F.R., 2011. Immunobiomarkers in small cell lung cancer: potential early cancer signals Clinical cancer research. 17(6), 1474-1480 CHAKRABARTI, J, KENNY, FS, SYED, BM, ROBERTSON, JFR, BLAMEY, RW and CHEUNG, KL, 2011. A Randomised Trial Of Mastectomy Only Versus Tamoxifen For Treating Elderly Patients With Operable Primary Breast Cancer-Final Results At 20-Year Follow-Up TOI, M, WINER, EP, INAMOTO, T, BENSON, JR, FORBES, JF, MITSUMORI, M, ROBERTSON, JFR, SASANO, H, VON MINCKWITZ, G, YAMAUCHI, A and KLIMBERG, VS, 2011. Identifying Gaps In The Locoregional Management Of Early Breast Cancer: Highlights From The Kyoto Consensus Conference Annals Of Surgical Oncology. 18(10), 2885-2892 CHEUNG, K.L., AGRAWAL, A., FOLKERD, E., DOWSETT, M., ROBERTSON, J.F.R. and WINTERBOTTOM, L., 2010. Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women European Journal of Cancer. 46(16), 2936-2942 BOYLE P, CHAPMAN CJ, HOLDENRIEDER S, MURRAY A, ROBERTSON C, WOOD WC, MADDISON P, HEALEY G, FAIRLEY GH, BARNES AC and ROBERTSON JFR, 2010. Clinical validation of an autoanibody test for lung cancer (In Press.)
ROBERTSON JFR, STEGER GG, NEVEN P, BARNI S, GIESEKING F, NOLE F, PRITCHARD KI and O'MALLEY FP, 2010. Activity of fulvestrant in HER2-overexpressing advanced breast cancer Annals of Oncology. 21(6), 1246-53 GUTTERIDGE, E., AGRAWAL, A., NICHOLSON, R., CHEUNG, K.L., ROBERTSON, J. and GEE, J., 2010. The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study International Journal of Cancer. 126(8), 1806-1816 MURRAY, A., CHAPMAN, C.J., HEALEY, G., PEEK, L.J., PARSONS, G., BALDWIN, D., BARNES, A., SEWELL, H.F., FRITSCHE, H.A. and ROBERTSON, J.F.R., 2010. Technical validation of an autoantibody test for lung cancer Annals Of Oncology. 21(8), 1687-1693 DUFFY, S.W., MACKAY, J., ANDERSON, E., EVANS, D.G., FIELDER, H., FOX, R., GRAY, J., GUI, G., MACMILLAN, D., MOSS, S., ROGERS, C., SAINSBURY, R., SIBBERING, M., BOGGIS, C. and BURN, J., 2010. Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single-arm, FH01 study Lancet Oncology. 11(12), 1127-1134 GEE, J.M.W., ELORANTA, J.J., IBBITT, J.C., ROBERTSON, J.F.R., ELLIS, I.O., WILLIAMS, T., NICHOLSON, R.I. and HURST, H.C., 2009. Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival Journal of Pathology. 217(1), 32-41 MATHEW, J, AGRAWAL, A, ASGEIRSSON, KS, BUHARI, SA, JACKSON, LR, CHEUNG, KL and ROBERTSON, JFR, 2009. Primary Endocrine Therapy In Locally Advanced Breast Cancers-The Nottingham Experience Breast Cancer Research And Treatment. 113(2), 403-407 AGRAWAL, A, HANNON, RA, CHEUNG, KL, EASTELL, R and ROBERTSON, JFR, 2009. Bone Turnover Markers In Postmenopausal Breast Cancer Treated With Fulvestrant - A Pilot Study Breast. 18(3), 204-207 MATHEW J, ASGEIRSSON KS, JACKSON LR, CHEUNG KL and ROBERTSON JFR, 2009. Neoadjuvant endocrine treatment in primary breast cancer – review of literature Breast. 18(6), 339-44 GUTTERIDGE E, 2009. Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors. Breast Cancer Res. 11(Suppl 3), S24
ROBERTSON, J.F.R., LLOMBART-CUSSAC, A., ROLSKI, J., FELTL, D., DEWAR, J., MACPHERSON, E., LINDEMANN, J. and ELLIS, M.J., 2009. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study Journal Of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 27(27), 4530-4535 RAKHA, EMAD A, EL-SAYED, MAYSA E, POWE, DESMOND G, GREEN, ANDREW R, HABASHY, HANY, GRAINGE, MATTHEW J, ROBERTSON, JOHN F R, BLAMEY, ROGER, GEE, JULIA, NICHOLSON, ROBERT I, LEE, ANDREW H S and ELLIS, IAN, 2008. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. European Journal of Cancer. 44(1), 73-83 BRISTOW, A R, AGRAWAL, A, EVANS, A J, BURRELL, H C, CORNFORD, E J, JAMES, J J, HAMILTON, L, ROBERTSON, J F R, CHAN, S Y, LAWTON, P A and CHEUNG, K L, 2008. Can computerised tomography replace bone scintigraphy in detecting bone metastases from breast cancer? A prospective study. Breast. 17(1), 98-103 MATHEW,, AGRAWAL,, ASGEIRSSON,, BUHARI,, JACKSON,, CHEUNG, and ROBERTSON,, 2008. Primary endocrine therapy in locally advanced breast cancers-the Nottingham experience. Breast Cancer Research and Treatment. 113, 403-7 MATHEW,, ASGEIRSSON,, CHEUNG,, CHAN,, DAHDA, and ROBERTSON,, 2008. Neoadjuvant chemotherapy for locally advanced breast cancer: A review of the literature and future directions. European Journal of Surgical Oncology. 35, 113-22
CHAPMAN, C.J., MURRAY, A., MCELVEEN, J.E., SAHIN, U., LUXEMBURGER, U., TÜRECI, O., WIEWRODT, R., BARNES, A.C. and ROBERTSON, J.F., 2008. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure Thorax. 63(3), 228-233 CHIA, S., GRADISHAR, W., MAURIAC, L., BINES, J., AMANT, F., FEDERICO, M., FEIN, L., ROMIEU, G., BUZDAR, A., ROBERTSON, J.F.R., BRUFSKY, A., POSSINGER, K., RENNIE, P., SAPUNAR, F., LOWE, E. and PICCART, M., 2008. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT Journal of Clinical Oncology. 26(10), 1664-1670 MORGAN, DAVID A L and ROBERTSON, JOHN F R, 2008. Boost or not. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(6), 1013-4; author reply 1014
STORR, SARAH J, ROYLE, LOUISE, CHAPMAN, CAROLINE J, HAMID, UMI M ABD, ROBERTSON, JOHN F, MURRAY, ANDREA, DWEK, RAYMOND A and RUDD, PAULINE M, 2008. The O-linked glycosylation of secretory/shed MUC1 from an advanced breast cancer patient's serum. Glycobiology. 18(6), 456-62
SHAABAN, A.M., GREEN, A.R., KARTHIK, S., ALIZADEH, Y., HUGHES, T.A., HARKINS, L., ELLIS I.O., ROBERTSON, J.F., PAISH, E.C., SAUNDERS, P.T.K., GROOME, N.P. and SPEIRS, V., 2008. Nuclear and cytoplasmic expression of ERβ1, ERβ2, and ERβ5 identifies distinct prognostic outcome for breast cancer patients Clinical Cancer Research. 14(16), 5228-5235 ABD HAMID UM, ROYLE L, SALDOVA R, RADCLIFFE CM, HARVEY DJ, STORR SJ, PARDO M, ANTROBUS R, CHAPMAN CJ, ZITZMANN N and ROBERTSON JFR, 2008. A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression Glycogiology. 18(12), 1150-18
NADERI, A., TESCHENDORFF, A.E., BARBOSA-MORAIS, N.L., PINDER, S.E., GREEN, A.R., POWE, D.G., ROBERTSON, J.F.R., APARICIO, S., ELLIS, I.O., BRENTON, J.D. and CALDAS, C., 2007. A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene. 26(10), 1507-1516 RAKHA, E.A., EL-SAYED, M.E., GREEN, A.R., PAISH, E.C., POWE, D.G., GEE, J., NICHOLSON, R.I., LEE, A.H.S., ROBERTSON, J.F.R. and ELLIS, I.O., 2007. Biologic and clinical characteristics of breast cancer with single hormone receptor-positive phenotype. Journal of Clinical Oncology. 25(30), 4772-4778 RAKHA, EMAD A, EL-SAYED, MAYSA E, GREEN, ANDREW R, LEE, ANDREW H S, ROBERTSON, JOHN F and ELLIS, IAN O, 2007. Prognostic markers in triple-negative breast cancer. Cancer. 109(1), 25-32 ASGEIRSSON, KRISTJAN S, AGRAWAL, AMIT, ALLEN, CLAIRE, HITCH, ANTHONY, ELLIS, IAN O, CHAPMAN, CAROLINE, CHEUNG, KWOK L and ROBERTSON, JOHN FR, 2007. Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients. Breast cancer research : BCR. 9(6), R75
MATHEW,, ASGEIRSSON,, AGRAWAL,, MUKHERJEE,, ELLIS,, CHEUNG,, CHAN, and ROBERTSON,, 2007. Neoadjuvant chemotherapy in locally advanced primary breast cancers - The Nottingham experience. European Journal of Surgical Oncology. HODI, ZSOLT, CHAKRABARTI, JAYETA, LEE, ANDREW H S, RONAN, JOHN E, ELSTON, CHRISTOPHER W, CHEUNG, KWOK LEUNG, ROBERTSON, JOHN F R and ELLIS, IAN O, 2007. The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast. Journal of Clinical Pathology. 60(3), 299-302 AGRAWAL, AMIT, CHEUNG, KWOK-LEUNG and ROBERTSON, JOHN F R, 2007. Fulvestrant in advanced male breast cancer. Breast Cancer Research and Treatment. 101(1), 123 CHIN, S-F, WANG, Y, THORNE, N P, TESCHENDORFF, A E, PINDER, S E, VIAS, M, NADERI, A, ROBERTS, I, BARBOSA-MORAIS, N L, GARCIA, M J, IYER, N G, KRANJAC, T, ROBERTSON, J F R, APARICIO, S and TAVARÉ, S, 2007. Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers. Oncogene. 26(13), 1959-70 ASSENDER, J W, GEE, J M W, LEWIS, I, ELLIS, I O, ROBERTSON, J F R and NICHOLSON, R I, 2007. Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer. Journal of clinical pathology. 60(11), 1216-21 VALASSIADOU, KALLIOPE, MORGAN, DAVID AL, ROBERTSON, JOHN FR, PINDER, SARAH E and CHEUNG, KWOK-LEUNG, 2007. Successful management of elderly breast cancer patients treated without radiotherapy. World Journal of Surgical Oncology. 5, 62 TAYLOR,, MORGAN,, SMART,, ZAHARI,, PUMFORD,, ELLIS,, ROBERTSON, and NICHOLSON,, 2007. The emerging role of the LIV-1 subfamily of zinc transporters in breast cancer. Molecular Medicine. BLAMEY, R W, ELLIS, I O, PINDER, S E, LEE, A H S, MACMILLAN, R D, MORGAN, D A L, ROBERTSON, J F R, MITCHELL, M J, BALL, G R, HAYBITTLE, J L and ELSTON, C W, 2007. Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. European Journal of Cancer. 43(10), 1548-55 HUTCHESON,, KNOWLDEN,, HISCOX,, BARROW,, GEE,, ROBERTSON,, ELLIS, and NICHOLSON,, 2007. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. 9(4), R50 RAMPAUL,, DALE,, MITCHELL,, BLAMEY,, MACMILLAN,, ROBERTSON, and ELLIS,, 2007. Incidence of intramammary nodes in completion mastectomy specimens after axillary node sampling: Implications for breast conserving surgery. Breast. AGRAWAL, A, AYANTUNDE, A A, RAMPAUL, R and ROBERTSON, J F R, 2007. Male breast cancer: a review of clinical management. Breast Cancer Research and Treatment. 103(1), 11-21 ROBERTSON, JOHN F R, 2007. Fulvestrant (Faslodex) -- how to make a good drug better. The oncologist. 12(7), 774-84
ROBERTSON, J F R, SEMIGLAZOV, V, NEMSADZE, G, DZAGNIDZE, G, JANJALIA, M, NICHOLSON, R I, GEE, J M W, ARMSTRONG, J and ,, 2007. Effects of fulvestrant 250mg in premenopausal women with oestrogen receptor-positive primary breast cancer. European Journal of Cancer. 43(1), 64-70 PARSY, CÉLINE B, CHAPMAN, CAROLINE J, BARNES, ANTONY C, ROBERTSON, JOHN F and MURRAY, ANDREA, 2007. Two-step method to isolate target recombinant protein from co-purified bacterial contaminant SlyD after immobilised metal affinity chromatography. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 853(1-2), 314-9 KUMARI, RAJENDRA, ROBERTSON, JOHN F and WATSON, SUSAN A, 2006. Nuclear targeting of a midregion PTHrP fragment is necessary for stimulating growth in breast cancer cells International Journal of Cancer. 119(1), 49-59 RAKHA, E.A., PUTTI, T.C., ABD EL-REHIM, D.M., PAISH, C., GREEN, A.R., POWE, D.G., LEE, A.H., ROBERTSON, J.F. and ELLIS, I.O, 2006. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation Journal of Pathology. 208(4), 495-506 STORR, S.J, CHAKRABARTI, J., BARNES, A., MURRAY, A., CHAPMAN, C.J and ROBERTSON, J.F.R, 2006. Use of autoantibodies in breast cancer screening and diagnosis. Expert review of anticancer therapy. 6(8), 1215-23 CHAPMAN,C., MURRAY,A., MCELVEEN,J., SAHIN,U., LUXEMBURGER,U., TURECI,O., WIEWRODT,R., BARNES,A. and ROBERTSON,J., 2006. Autoantibodies in lung cancer. Tumor Biology. 27(Suppl 1), 41 GUTTERIDGE, E., AGRAWAL, A., CHEUNG, K.L., HYMAN-TAYLOR, P., EVANS, A. and ROBERTSON, J.F.R., 2006. Early use of fulvestrant for the treatment of postmenopausal women with advanced breast cancer - the Nottingham experience European Journal of Cancer Supplement. 4(2), 162 AGRAWAL, AMIT, ROBERTSON, JOHN F R and CHEUNG, K L, 2006. Efficacy and tolerability of high dose "ethinylestradiol" in post-menopausal advanced breast cancer patients heavily pre-treated with endocrine agents. World Journal of Surgical Oncology. 4, 44
RAKHA, EMAD A, EL-REHIM, DALIA ABD, PAISH, CLAIRE, GREEN, ANDREW R, LEE, ANDREW H S, ROBERTSON, JOHN F, BLAMEY, ROGER W, MACMILLAN, DOUGLAS and ELLIS, IAN O, 2006. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. European Journal of Cancer. 42(18), 3149-56 AGRAWAL, AMIT, ROBERTSON, JOHN F R and CHEUNG, K L, 2006. "Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer. World Journal of Surgical Oncology. 4, 40
CHEUNG, K.L. and ROBERTSON, J., 2006. Surgery in early breast cancer. In: Lectures in early breast cancer London: Current Medicine Group. 1-6
CHAPMAN,C., MURRAY,A., MCELVEEN,J., CHAKRABARTI,J., ALLEN,C., WOOLSTON,C., BARNES,A., SAHIN,U., ELLIS,I. and ROBERTSON,J.F.R., 2006. Autoantibodies in Early Breast Cancer. Tumor Biology. 27(Suppl 2), 57 (In Press.)
EL-REHIM, D.M.A., BALL, G., PINDER, S.E., RAKHA, E., PAISH, C., ROBERTSON, J.F.R., MACMILLAN, D., BLAMEY, R.W. and ELLIS, I.O., 2005. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses International Journal of Cancer. 116(3), 340-350 HOWELL, A., PIPPEN, J., ELLEDGE, R.M., MAURIAC, L., VERGOTE, I., JONES, S.E., COME, S.E., OSBORNE, C.K. and ROBERTSON, J.F.R., 2005. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials Cancer. 104(2), 236-239 GRAVES, C.R.L., ROBERTSON, J.F.R, MURRAY, A., PRICE, M.R. and CHAPMAN, C.J., 2005. Malignancy-induced autoimmunity to MUC1: initial antibody characterization. Journal of Peptide Research. 66(6), 357-363 ASGEIRSSON, K.S., HOLROYD, B., MORGAN, D.A.L., ROBERTSON, J.F.R., BLAMEY, R.W., PINDER, S.E. and MACMILLAN, R.D, 2005. Selective use of post-mastectomy flap irradiation in high-risk breast cancer patients. Breast. 14(4), 298-303 ROBERTSON, J.F.R., CHAPMAN, C.J., CHEUNG, K.L., MURRAY, A., PINDER, S.E., PRICE, M.R. and GRAVES, R.L., 2005. Auto-antibodies in early breast cancer Journal of Clinical Oncology. 23(16S), 549
RAMPAUL, R. S., PINDER, S. E., NICHOLSON, R. I., GULLICK, W. J., ROBERTSON, J. F. and ELLIS, I. O., 2005. Clinical Value of Epidermal Growth Factor Receptor Expression in Primary Breast Cancer Advances in Anatomic Pathology. VOL 12(NUMB 5), 271-273 RAKHA, E. A., BOYCE, R. W. G., EL-REHIM, D. A., KURIEN, T., GREEN, A. R., PAISH, E. C., ROBERTSON, J. F. R. and ELLIS, I. O., 2005. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer Modern Pathology. VOL 18(ISSU 10), 1295-1304 ROBERTSON, J.F., GUTTERIDGE, E., CHEUNG, K.L., PINDER, S. and WAKELING, A., 2005. Effects of fulvestrant on estrogen receptor levels during long-term treatment of patients with advanced breast cancer - final results British Journal of Surgery. 92(Supplement 1), 29
GEE, J. M. W., ROBERTSON, J. F. R., GUTTERIDGE, E., ELLIS, I. O., PINDER, S. E., RUBINI, M. and NICHOLSON, R. I., 2005. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer Endocrine-Related Cancer. VOL 12(SUPP/1), S99-S111 AGRAWAL, A., GUTTERIDGE, E., GEE, J. M. W., NICHOLSON, R. I. and ROBERTSON, J. F. R., 2005. Overview of tyrosine kinase inhibitors in clinical breast cancer Endocrine-Related Cancer. VOL 12(SUPP/1), S135-S144 CROOK, S.J., BROOK, J.D., SOMMER, A., KREZSCHMAR, J. and ROBERTSON, J.F., 2005. Identification of genes regulated by the antiprogestin, Onapristone, in breast cancer cells using microarray analysis. In: LI, J.J., LI, S.A. and LLOMBART-BOSCH, A., eds., Hormonal Carcinogenesis IV Springer Verlag. 308-313
ROBERTSON, J F R, COME, S E, JONES, S E, BEEX, L, KAUFMANN, M, MAKRIS, A, NORTIER, J W R, POSSINGER, K and RUTQVIST, L-E, 2005. Endocrine treatment options for advanced breast cancer--the role of fulvestrant. European Journal of Cancer. 41(3), 346-56 ROBERTSON,J.F., HOWELL,A., GORBUNOVA,V.A., WATANABE,T., PIENKOWSKI,T. and LICHINITSER,M.R., 2005. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant Breast Cancer Research and Treatment. 92(2), 169-74 GEE, J.M., GUTTERIDGE, E., ROBERTSON, J.F., WAKELING, A.E., JONES, H.E. and NICHOLSON, R.I., 2005. Biological markers during early treatment of tamoxifen resistant breast cancer with gefitinib British Journal of Surgery. 92(Supplement 1), 13
GEE, J M W, HOWELL, A, GULLICK, W J, BENZ, C C, SUTHERLAND, R L, SANTEN, R J, MARTIN, L-A, CIARDIELLO, F, MILLER, W R, DOWSETT, M, BARRETT-LEE, P, ROBERTSON, J F R, JOHNSTON, S R, JONES, H E, WAKELING, A E, DUNCAN, R and NICHOLSON, R I, 2005. Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment. Endocrine-Related Cancer. 12 Suppl 1, S1-7
EL-REHIM, D.M.A., PINDER, S.E., PAISH, C.E., BELL, J., BLAMEY, R.W., ROBERTSON, J.F.R., NICHOLSON, R.I. and ELLIS, I.O., 2004. Expression of luminal and basal cytokeratins in human breast carcinoma Journal of Pathology. 203(2), 661-671 HOWELL, A., ROBERTSON, J.F.R., ABRAM, P., LICHINITSER, M.R., ELLEDGE, R., BAJETTA, E., WATANABE, T., MORRIS, C., WEBSTER, A., DIMERY, I. and OSBORNE, C.K., 2004. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. Journal of Clinical Oncology. 22(9), 1605-1613 EL-REHIM, D. M. A., PINDER, S. E., PAISH, C. E., BELL, J. A., RAMPAUL, R. S., BLAMEY, R. W., ROBERTSON, J. F. R., NICHOLSON, R. I. and ELLIS, I. O., 2004. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma British Journal of Cancer. VOL 91(NUMB 8), 1532-1542 HAMILTON, L J, EVANS, A J, PINDER, S E, JAMES, J J, GUTTERIDGE, E, CORNFORD, E J, BURRELL, H C, CHAN, S Y, ROBERTSON, J F and CHEUNG, K L, 2004. Metastatic carcinoma of the breast with tubular features: differences compared with metastatic ductal carcinoma of no specific type. Clinical Oncology. 16(2), 119-24 EVANS, A. J., JAMES, J. J., CORNFORD, E. J., CHAN, S. Y., BURRELL, H. C., PINDER, S. E., GUTTERIDGE, E., ROBERTSON, J. F., HORNBUCKLE, J. and CHEUNG, K. L., 2004. Brain metastases from breast cancer: identification of a high-risk group Clinical Oncology. VOL 16(NUMBER 5), 345-349 GREEN,A.R., PAISH,E.C., GEE,J.M., NICHOLSON,R.I., CHEUNG,K.L., ROBERTSON,J.F. and ELLIS,I.O., 2004. Oestrogen receptor variant expression as potential selectors for adjuvant endocrine therapy in breast cancer patients: The 187th Meeting of the Pathological Society of Great Britain and Ireland, The Robin Brook Centre, St. Bartholomew's Hospital, London, 6-7 January 2005 Journal of Pathology. 205(S1), 5A
PANIGRAHI, A. R., PINDER, S., CHAN, S. Y., PAISH, E. C., ROBERTSON, J. F. R. and ELLIS, I. O., 2004. The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome Journal of Pathology. VOL 204(PART 1), 93-100 RAKHA, E. A., PINDER, S. E., PAISH, E. C., ROBERTSON, J. F. and ELLIS, I. O., 2004. Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosis Journal of Pathology. VOL 203(NUMB 3), 754-761 FELTON, T., HARRIS, G. C., PINDER, S. E., SNEAD, D. R., CARTER, G. I., BELL, J. A., HAINES, A., KOLLIAS, J., ROBERTSON, J. F. and ELSTON, C. W., 2004. Identification of carcinoma cells in peripheral blood samples of patients with advanced breast carcinoma using RT-PCR amplification of CK7 and MUC1 Breast. VOL 13(NUMBER 1), 35-41 ROBERTSON, J.F., GUTTERIDGE, E., CHEUNG, K.L., PINDER, S.E. and WAKELING, A., 2004. Oestrogen receptor changes during treatment with fulvestrant (Faslodex) Program and Proceedings of ASCO Annual Meeting. 536
PORTER, G. J., EVANS, A. J., PINDER, S. E., JAMES, J. J., CORNFORD, E. C., BURRELL, H. C., CHAN, S. Y., CHEUNG, K. L. and ROBERTSON, J. F., 2004. Patterns of metastatic breast carcinoma: influence of tumour histological grade Clinical Radiology. VOL 59(NUMBER 12), 1094-1098 ROBERTSON, J F R and HARRISON, M, 2004. Fulvestrant: pharmacokinetics and pharmacology. British Journal of Cancer. 90 Suppl 1, S7-10 RUSHMERE, NEIL K, KNOWLDEN, JANICE M, GEE, JULIA M W, HARPER, MAUREEN E, ROBERTSON, JOHN F, MORGAN, B PAUL and NICHOLSON, ROBERT I, 2004. Analysis of the level of mRNA expression of the membrane regulators of complement, CD59, CD55 and CD46, in breast cancer. International Journal of Cancer. 108(6), 930-6 ROBERTSON, JOHN F R, ERIKSTEIN, BJORN, OSBORNE, KENT C, PIPPEN, JOHN, COME, STEVEN E, PARKER, LEROY M, GERTLER, STAN, HARRISON, MIKE P and CLARKE, DAVID A, 2004. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer. Clinical Pharmacokinetics. 43(8), 529-38 EVANS, A.J., JAMES, J.J., CORNFORD, E., CHAN, S., BURRELL, H., PINDER, S.E., GUTTERIDGE, E., ROBERTSON, J.F., HORNBUCKLE, J. and CHEUNG, K.L., 2003. Brain metastases from breast cancer: identification of a high risk group In: British Breast Group Meeting.
BARNES, A., PINDER, S. E., BELL, J. A., PAISH, E. C., WENCYK, P. M., ROBERTSON, J. F. R., ELSTON, C. W. and ELLIS, I. O., 2003. Expression of p27kip1 in breast cancer and its prognostic significance Journal of Pathology. VOL 201(PART 3), 451-459 JAMES,J.J., EVANS,A.J., PINDER,S.E., GUTTERIDGE,E., CHEUNG,K.L., CHAN,S.Y. and ROBERTSON,J.F., 2003. Bone metastases from breast carcinoma: Histopathological-radiological correlations and prognostic features European Journal of Cancer. 89(4), 660-665
GUTTERIDGE, E., PRINSLOO, P., MARENAH, C., SCOTT, N., ROBERTSON, J.F. and CHEUNG, K.L., 2003. A pilot study of early intervention based on tumour markers in the follow up of patients with primary breast cancer - preliminary report In: 8th Nottingham International Breast Cancer Conference.
ROBERTSON, J.F., GUTTERIDGE, E., CHEUNG, K.L., OWERS, R., KOEHLER, M., HAMILTON, L., GEE, J. and NICHOLSON, R.I., 2003. Gefitinib ('Iressa', ZD1839) is active in acquired tamoxifen-resistant oestrogen receptor-positive and oestrogen receptor-negative breast cancer: results from a Phase II study Program and Proceedings of ASCO Annual Meeting. 23
WYLD, L, GUTTERIDGE, E, PINDER, S E, JAMES, J J, CHAN, S Y, CHEUNG, K L, ROBERTSON, J F R and EVANS, A J, 2003. Prognostic factors for patients with hepatic metastases from breast cancer. British Journal of Cancer. 89(2), 284-90 GUTTERIDGE, E., CHEUNG, K.L., OWERS, R., KOEHLER, M., HAMILTON, L., GEE, J., NICHOLSON, R.I. and ROBERTSON, J.F., 2003. Gefitinib ('Iressa', ZD1839) has activity in patients with oestrogen receptor-negative breast cancer and oestrogen receptor-positive breast cancer that has acquired resistance to tamoxifen: results from a Phase II study European Journal of Cancer. 1(4 (suppl)), 0-36
GUTTERIDGE, E., EVANS, A.J., JAMES, J.J., CHAN, S.Y., ROBERTSON, J.F. and CHEUNG, K.L., 2003. Parenchymal and pleural metastases in breast cancer - prognostic features In: 8th Nottingham International Breast Cancer Conference.
JAMES, J J, EVANS, A J, PINDER, S E, GUTTERIDGE, E, CHEUNG, K L, CHAN, S and ROBERTSON, J F R, 2003. Bone metastases from breast carcinoma: histopathological - radiological correlations and prognostic features. British Journal of Cancer. 89(4), 660-5 KHAN, H N, WYLD, L, DUNNE, B, LEE, A H S, PINDER, S E, EVANS, A J and ROBERTSON, J F R, 2003. Spindle cell carcinoma of the breast: a case series of a rare histological subtype. European Journal of Surgical Oncology. 29(7), 600-3 KUMAR, I.D., FORWARD, D.P., KENNY, F., ROBERTSON, J.F. and CHEUNG, K.L., 2003. The potential use of blood tumour markers in monitoring therapeutic response in elderly primary breast cancer In: 8th Nottingham International Breast Cancer Conference.
CHEUNG, K. L. and ROBERTSON, F. R., 2003. Objective measurement of remission and progression in metastatic breast cancer by the use of serum tumour markers Minerva Chirurgica. VOL 58(PART 3), 297-304
VERGOTE, I, ROBERTSON, J F R, KLEEBERG, U, BURTON, G, OSBORNE, C K, MAURIAC, L, , and ,, 2003. Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy. Breast Cancer Research and Treatment. 79(2), 207-11 NABHOLTZ, J. M., BONNETERRE, J., BUZDAR, A., ROBERTSON, J. F. R., THURLIMANN, B. and ARIMIDEX WRITING COMMITTEE ON BEHALF OF THE INVESTIGATORS, 2003. Anastrozole (ArimidexTM) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results European Journal of Cancer. VOL 39(PART 12), 1684-1689 ROBERTSON, J. F., ODLING-SMEE, W., HOLCOMBE, C., KOHLHARDT, S. R. and HARRISON, M. P., 2003. Pharmacokinetics of a single dose of fulvestrant prolonged-release intramuscular injection in postmenopausal women awaiting surgery for primary breast cancer Clinical Therapeutics. VOL 25(NUMBER 5), 1440-1452 ROBERTSON, JOHN F R, OSBORNE, C KENT, HOWELL, ANTHONY, JONES, STEPHEN E, MAURIAC, LOUIS, ELLIS, MATTHEW, KLEEBERG, ULRICH R, COME, STEVEN E, VERGOTE, IGNACE, GERTLER, STAN, BUZDAR, AMAN, WEBSTER, ALAN and MORRIS, CHARLES, 2003. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer. 98(2), 229-38 HOWELL, A., ROBERTSON, J. F. and VERGOTE, I., 2003. A Review of the Efficacy of Anastrozole in Postmenopausal Women with Advanced Breast Cancer with Visceral Metastases Breast Cancer Research and Treatment. VOL 82(NUMBER 3), 215-222 THüRLIMANN, B, ROBERTSON, J F R, NABHOLTZ, J M, BUZDAR, A, BONNETERRE, J and ,, 2003. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. European Journal of Cancer. 39(16), 2310-7 CHEUNG,K.L., GRAVES,C.R. and ROBERTSON,J.F.R., 2002. Autoantibodies as circulating cancer markers. In: Tumor Markers - Physiology, Pathobiology, Technology and Clinical Applications AACC Press, Washington. 123-132
CHEUNG,K.L. and ROBERTSON,J.F.R., 2002. Endocrine Therapy for Metastatic Breast Cancer : case studies Nova Professional Media, Faringdon.
MIREMADI, A., PINDER, S. E., LEE, A. H. S., BELL, J. A., PAISH, E. C., WENCYK, P., ELSTON, C. W., NICHOLSON, R. I., BLAMEY, R. W. and ROBERTSON, J. F., 2002. Neuroendocrine differentiation and prognosis in breast adenocarcinoma Histopathology. VOL 40(PART 3), 215-222 VALASSIADOU, K., MORGAN, D.A., PINDER, S.E., BLAMEY, R.W., CHEUNG, K.L., MACMILLAN, R.D. and ROBERTSON, J.F., 2002. Efficacy of breast conserving surgery without adjuvant radiotherapy for invasive breast cancer in the elderly In: Annual Scientific Conference 2002 of the British Association of Surgical Oncology.
RAMPAUL, R. S., PINDER, S. E., GULLICK, W. J., ROBERTSON, J. F. and ELLIS, I. O., 2002. HER-2 in breast cancer-methods of detection, clinical significance and future prospects for treatment Critical Reviews in Oncology/Hematology. VOL 43(NUMBER 3), 231-244 KHAN, H., WYLD, L., PINDER, S., EVANS, A., CHEUNG, K. L. and ROBERTSON, J. F. R., 2002. Spindle cell carcinoma of the breast: an uncommon histological type, which should not be under-estimated European Journal of Surgical Oncology. VOL 28(NO 7), P3
WYLD, L., GUTTERIDGE, E., PINDER, S., JAMES, J. J., CHAN, S. Y., CHEUNG, K. L., ROBERTSON, J. F. R. and EVANS, A., 2002. Liver metastases from breast cancer: prognostic factors European Journal of Surgical Oncology. VOL 28(NO 7), 7
ROBERTSON, J. F., GUTTERIDGE, E., CHEUNG, K. L., OWERS, R. and KOEHLER, M., 2002. A Phase II study of ZD1839 (`Iressa') in tamoxifen-resistant ER-positive and endocrine-insensitive (ER-negative) breast cancer Breast Cancer Research and Treatment. VOL 76(SUPPL 1), 357
CHEUNG, K.L., ROBERTSON, J.F., SCOTT, N. and OWERS, R., 2002. Endocrine response after prior treatment with fulvestrant (Faslodex) in postmenopausal women with advanced breast cancer European Journal of Cancer. 38 (Suppl 3)(225), S98
CHEUNG, K.-L. and ROBERTSON, J. F., 2002. Treatment Options For Postmenopausal Women with Tamoxifen-Resistant Advanced Breast Cancer American Journal of Cancer. VOL 1(NUMB 4), 293-300 CHEUNG, K.L., FORWARD, D.P. and ROBERTSON, J.F., 2002. Clinical and endocrine data for goserelin (Zoladex) plus anastrozole (Arimidex) as second line endocrine therapy in premenopausal women with advanced breast cancer Breast Cancer Research and Treatment. 69(289), 450
CHEUNG, KWOK LEUNG and ROBERTSON, JOHN F R, 2002. Fulvestrant. Expert Opinion on Investigational Drugs. 11(2), 303-8 CHEUNG, K. L., CHAN, S. Y., EVANS, A. J., WINTERBOTTOM, L. and ROBERTSON, J. F. R., 2002. Management of advanced breast cancer - a multidisciplinary approach Hong Kong Practitioner. VOL 24(PART 3), 114-131
BUZDAR, AMAN U, ROBERTSON, JOHN F R, EIERMANN, WOLFGANG and NABHOLTZ, JEAN-MARC, 2002. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer. 95(9), 2006-16 HOWELL, A, ROBERTSON, J F R, QUARESMA ALBANO, J, ASCHERMANNOVA, A, MAURIAC, L, KLEEBERG, U R, VERGOTE, I, ERIKSTEIN, B, WEBSTER, A and MORRIS, C, 2002. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. Journal of Clinical Oncology. 20(16), 3396-403 ROBERTSON, JOHN F R, 2002. Current role of endocrine therapy in the management of breast cancer. Breast Cancer: The Journal of the Japanese Breast Cancer Society. 9(4), 276-81
BUNDRED, N. J., ANDERSON, E., NICHOLSON, R. I., DOWSETT, M., DIXON, M. and ROBERTSON, J. F., 2002. Fulvestrant, an Estrogen Receptor Downregulator, Reduces Cell Turnover Index More Effectively than Tamoxifen Anticancer Research. VOL 22(PART 4), 2317-2320
KENNY, F. S., GEE, J. M. W., NICHOLSON, R. I., ELLIS, I. O., MORRIS, T. M., WATSON, S. A., BRYCE, R. P. and ROBERTSON, J. F. R., 2001. Effect of dietary GLA+/-tamoxifen on the growth, ER expression and fatty acid profile of ER positive human breast cancer xenografts International Journal of Cancer. VOL 92(PART 3), 342-347 CHEUNG, K.L., NICHOLSON, R.I., BLAMEY, R.W. and ROBERTSON, J.F.R., 2001. Selection of primary breast cancer patients for adjuvant endocrine therapy-is oestrogen receptor alone adequate? Breast Cancer Research and Treatment. 65(2), 155-162 TAN, S M, CHEUNG, K L, WILLSHER, P C, BLAMEY, R W, CHAN, S Y and ROBERTSON, J F, 2001. Locally advanced primary breast cancer: medium-term results of a randomised trial of multimodal therapy versus initial hormone therapy. European Journal of Cancer. 37(18), 2331-8 PARKER, C., RAMPAUL, R. S., PINDER, S. E., BELL, J. A., WENCYK, P. M., BLAMEY, R. W., NICHOLSON, R. I., ROBERTSON, J. F. and ELLIS, I. O., 2001. E-cadherin as a prognostic indicator in primary breast cancer British Journal of Cancer. VOL 85(PART 12), 1958-1963 CROMBIE, N., RAMPAUL, R. S., PINDER, S. E., ELSTON, C. W., ROBERTSON, J. F. R. and ELLIS, I. O., 2001. Extent of ductal carcinoma in situ within and surrounding invasive primary breast carcinoma British Journal of Surgery. VOL 88(PART 10), 1324-1329 KENNY, F. S., WILLSHER, P. C., GEE, J. M., NICHOLSON, R. I., PINDER, S. E., ELLIS, I. O. and ROBERTSON, J. F., 2001. Change in expression of ER, bcl-2 and MIB1 on primary tamoxifen and relation to response in ER positive breast cancer Breast Cancer Research and Treatment. VOL 65(PART 2), 135-144 MACAFEE, D., CHEUNG, K.L., WILLSHER, P.C., NICHOLSON, R.I., GEE, J., PINDER, S.E. and ROBERTSON, J.F., 2001. Immunohistochemical features at secondary hormone resistance do not predict response to subsequent second-line hormone therapy for breast cancer In: 7th Nottingham International Breast Cancer Conference.
CHEUNG, K.L., TAN, S.M., WILLSHER, P.C., BLAMEY, R.W., CHAN, S.Y. and ROBERTSON, J.F., 2001. A prospective randomised trial of multimodal therapy versus initial hormone therapy for locally advanced primary breast cancer British Journal of Surgery. 88(supplement),
CHEUNG, K.L., OWERS, R., HOWELL, A. and ROBERTSON, J.F., 2001. Survival updates of a phase II study comparing long-acting ICI 182,780 (Faslodex) with megestrol acetate as second-line endocrine therapy for breast cancer In: 7th Nottingham International Breast Cancer Conference.
CHEUNG, K.L., FORWARD, D.P., JACKSON, L. and ROBERTSON, J.F., 2001. Combined use of goserelin (Zoladex) and anastrozole (Arimidex) as second-line endocrine therapy in premenopausal women with advanced breast cancer - A study of its clinical and endocrine effects European Journal of Cancer. 37 (Suppl 5)(8), 0-22
CHEUNG, K.L., FORWARD, D., JACKSON, L. and ROBERTSON, J.F., 2001. The combined use of goserelin and anastrozole as second line endocrine therapy in premenopausal women with advanced breast cancer - a study of its clinical and endocrine effects Program and Proceedings of ASCO Annual Meeting. 1937
CHEUNG, K L and ROBERTSON, J F, 2001. Preoperative hormone therapy trials for breast cancer. Breast. 10(1), 1-5 GION, M, MIONE, R, LEON, A E, LüFTNER, D, MOLINA, R, POSSINGER, K and ROBERTSON, J F, 2001. CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases. European Journal of Cancer. 37(3), 355-63 WHITLOCK, J P, EVANS, A J, JACKSON, L, CHAN, S Y and ROBERTSON, J F, 2001. Imaging of metastatic breast cancer: distribution and radiological assessment at presentation. Clinical Oncology. 13(3), 181-6 BONNETERRE, J, BUZDAR, A, NABHOLTZ, J M, ROBERTSON, J F, THüRLIMANN, B, VON EULER, M, SAHMOUD, T, WEBSTER, A, STEINBERG, M, , and ,, 2001. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 92(9), 2247-58 BONNETERRE, J., THURLIMANN, B., ROBERTSON, J. F. R., KRZAKOWSKI, M., MAURIAC, L., KORALEWSKI, P., VERGOTE, I., WEBSTER, A., STEINBERG, M. and VON EULER, M., 2000. Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study Journal of Clinical Oncology. VOL 18(PART 22), 3748-3757 GEE, J M, BARROSO, A F, ELLIS, I O, ROBERTSON, J F and NICHOLSON, R I, 2000. Biological and clinical associations of c-jun activation in human breast cancer. International Journal of Cancer. 89(2), 177-86 GONZALEZ, M. A., PINDER, S. E., WENCYK, P. M., BELL, J. A., ELSTON, C. W., NICHOLSON, R. I., ROBERTSON, J. F. R., BLAMEY, R. W. and ELLIS, I. O., 1999. An Immunohistochemical Examination of the Expression of E-Cadherin, à- and á/ç-Catenins, and à2- and á1-Integrins in invasive Breast Cancer Journal of Pathology. VOL 187(NUMBER 5), 523-529 KENNY,F.S., ELLIS,I.O., ROBERTSON,J.F., PINDER,S.E., NICHOLSON,R.I., GEE,J.M. and WILLSHER,P.C., 1999. Endocrine response and resistance in breast cancer: A role for the transcription factor Fos International Journal of Cancer. 84(1), 54-61
GEE, J. M. W., WILLSHER, P. C., KENNY, F. S., ROBERTSON, J. F. R., PINDER, S. E., ELLIS, I. O. and NICHOLSON, R. I., 1999. Endocrine response and resistance in breast cancer: A role for the transcription factor Fos International Journal of Cancer. VOL 84(NUMBER 1), 54-61 KNOWLDEN, J. M., GEE, J. M. W., SEERY, L. T., FARROW, L., GULLICK, W. J., ELLIS, I. O., BLAMEY, R. W., ROBERTSON, J. F. R. and NICHOLSON, R. I., 1998. c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer Oncogene. VOL 17(NUMB 15), 1949-1957 MACMILLAN, R. D. and ROBERTSON, J. F. R., 1998. Benign disorders of the female breast Current Obstetrics and Gynaecology. VOL 8(NUMBER 4), 209-217 GEE, J.M., ROBERTSON, J.F. and WILLSHER, P.C., 1998. Changes in expression of ER, PgR and PS2 protein during hormone therapy for primary breast cancer British Journal of Cancer.
CHEUNG, K L, BLAMEY, R W, ROBERTSON, J F, ELSTON, C W and ELLIS, I O, 1997. Subcutaneous mastectomy for primary breast cancer and ductal carcinoma in situ. European Journal of Surgical Oncology. 23(4), 343-7 MURRAY, A, WILLSHER, P, PRICE, M R, DIXON, A R and ROBERTSON, J F, 1997. Evaluation of the IMMULITE BR-MA and CEA assays and comparison with immunoradiometric assays for CA15-3 and CEA in breast cancer. Anticancer Research. 17(3C), 1945-9
ORMANDY, C J, HALL, R E, MANNING, D L, ROBERTSON, J F, BLAMEY, R W, KELLY, P A, NICHOLSON, R I and SUTHERLAND, R L, 1997. Coexpression and cross-regulation of the prolactin receptor and sex steroid hormone receptors in breast cancer. Journal of Clinical Endocrinology and Metabolism. 82(11), 3692-9